A Safety, Tolerability, and Efficacy Study of BMN 190 in Pediatric Patients < 18 Years of Age With CLN2 Disease

Clinical trial NCT02678689 · COMPLETED

Trial details

NCT number: NCT02678689
Sponsor: BioMarin Pharmaceutical
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Jansky-Bielschowsky Disease Batten Disease Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 CLN2 Disease CLN2 Disorder

Start date: 2016-01-22
Primary completion: 2022-04-20
Enrollment: 14

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.